research Eosinophilic folliculitis of the scalp associated with PD‐1/PDL1 inhibitors
Immune checkpoint inhibitors can cause scalp inflammation and hair follicle issues.
Search
for
Sort by
Research
30 / 397 resultsresearch 422 Human hair follicles express PD-L1, whose expression is down-regulated by EGFR and MEK inhibitors ex vivo. A potential mechanism for EGFR inhibitor induced sterile folliculitis
EGFR and MEK inhibitors reduce PD-L1 in hair follicles, possibly causing inflammation.
research ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
research IMMUNE-RELATED SKIN TOXICITIES TO CHECKPOINT INHIBITORS THERAPY
Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.
research Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.
research Risk of Autoimmune Skin Diseases Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis Using the FAERS Database
Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.
research LB1681 Risk of merkel cell carcinoma progression after treatment discontinuation in patients with an objective response to anti-PD-(L)1 immunotherapy
Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.
research Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.
research Cutaneous toxicities of new treatments for melanoma
New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.
research Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer
A cancer patient's hair became permanently curly after treatment with nivolumab.
research Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description
Nail changes from immunotherapy can be managed without stopping cancer treatment.
research El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
research Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy
Anti-PD-L1 immunotherapy can cause hair loss and unexpected hair color change, but treatment can restore hair growth and color.
research Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.
research 183 PD-1 regulatory network is upregulated in contact immunotherapy during alopecia areata treatment
Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.
research Alopecia Areata
Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.
research Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
research Tregs: Where We Are and What Comes Next?
The conclusion is that Treg-targeted therapies have potential, but more knowledge of Treg biology is needed for effective treatments, including for cancer.
research Adverse Hair Reactions to New Targeted Therapies for Cancer
New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
research Immune Microenvironment of Hair Follicles in Tumor Immunotherapy
Tumor immunotherapy can cause hair loss by disrupting hair follicle immunity.
research Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
research Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies
Animal models have helped understand hair loss from alopecia areata and find new treatments.
research Age-associated inflammation connects RAS-induced senescence to stem cell dysfunction and epidermal malignancy
Older skin has higher cancer risk due to inflammation and stem cell issues.
research Roles of tumor suppressors in regulating tumor-associated inflammation
Tumor suppressors help control inflammation in cancer and restoring their function could lead to new treatments.
research Inhibition of T-cell activity in alopecia areata: recent developments and new directions
New treatments targeting T-cell pathways are needed for better alopecia areata management.
research Enzyme Inhibitors from Gorgonians and Soft Corals
Marine compounds from gorgonians and soft corals show promise for drug development, especially for chronic disorders.
research Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
Cancer treatments often cause skin, nail, and hair problems.
research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
research Cancer Treatments and Alopecia: A Systematic Review
Cancer treatments often cause hair loss, and more research is needed to prevent and treat it.
research Dermatologic Adverse Events from Cancer Treatments
Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.